Impact of antimetabolite discontinuation following cytomegalovirus or BK polyoma virus infection in kidney transplant recipients.

Casey A Dubrawka Kristin J Progar Spenser E January Jennifer C Hagopian Nicole M Nesselhauf Andrew F Malone

Published in: Transplant infectious disease : an official journal of the Transplantation Society (2022)

These findings suggest that antimetabolite discontinuation after CMV or BKV DNAemia in kidney transplant recipients is a reasonable and safe approach. Further prospective studies investigating optimal immunosuppression management following CMV or BKV DNAemia in kidney transplant recipients are warranted.

Keyphrases

epstein barr virus
case control